2017-08-23
INTERIM REPORT FOR KANCERA AB (publ) JANUARI 1ST – JUNE 30TH 2017
This is a translation from the original report published in Swedish August 22nd 2017.
Read More
2017-05-09
Kancera announces approval for the start of clinical trial of KAND567
The Medical Ethics Committee (METC) at the University Medical Center in Groningen, The Netherlands, has approved the start of clinical Phase I study of KAND567. The first dose to humans will be given within the next few weeks.
Read More
2017-04-19
Kancera has applied for a clinical trial for KAND567
Kancera AB has applied for approval for a Phase I clinical trial. The study is planned to be conducted in collaboration with the clinical contract company QPS in Groningen, The Netherlands.
Read More
2017-04-12
Kancera provides an operational update of the PFKFB3 project
Kancera reports that PFKFB3-inhibitor KAN0438757 increases the effect of a promising class of drugs for intractable cancer. Kancera has strengthened their development of drugs directed against PFKFB3 and DNA repair through a new recruitment. The European and US patent...
Read More
2017-04-06
Kancera recruits two PhD students to the EU-funded research programme SYNTRAIN
Kancera AB (publ) has previously announced that the company has been awarded a research grant of approximately EUR 500 000, in the context of the EU research programme SYNTRAIN (a program within Horizon 2020), for the financing of two...
Read More
2017-04-04
Kancera completes acquisition of the Fractalkine project for autoimmune diseases and cancer
Kancera AB (publ) has previously announced the Board's decision to execute the company's exclusive option to acquire the Fractalkine project from Acturum Real Estate AB after transfer of results and know-how. This transfer of results and know-how has now...
Read More
2017-03-28
Kancera comments: Breakthrough for drug development targeting the Fractalkine system that controls immune cells and cancer cells
Blocking the Fractalkine system has been shown in clinical trials to have the desired effects in humans against intractable forms of autoimmune diseases. The results are in line with the positive effects that Kancera has been able to demonstrate...
Read More
2017-02-21
INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December 31st 2016
THE PERIOD JANUARY – DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income for the period amounted to SEK -22,3M (SEK -19.7M)...
Read More
2017-02-21
Kancera provides operational update of the project portfolio
Kancera AB (publ) presents new information on - how the company's Fractalkine blocker prevents immune cells (monocytes) to infiltrate the nerves and spinal cord, which prevents nerve damage and enhanced pain sensitivity associated with cancer treatment - the fact...
Read More
2016-12-29
Kancera appoints Joachim Forsgren as Chief Medical Officer
This is a translation from a swedish press release Stockholm dated 2016-12-23. Kancera AB (publ) today announced that Joachim Forsgren (MD, PhD) has been appointed Chief Medical Officer and will be medically responsible for Kancera product portfolio. He will...
Read More